Feasibility and efficacy of eribulin mesilate in Korean patients with metastatic breast cancer

Korean multi-center phase IV clinical study results

Yeon Hee Park, Tae Yong Kim, Young Hyuck Im, Keun Seok Lee, In Hae Park, Joohyuk Sohn, Soo Hyeon Lee, Seock Ah Im, Jee Hyun Kim, Se Hyun Kim, Soo Jung Lee, Su Jin Koh, Ki Hyeong Lee, Yoon Ji Choi, Eun Kyung Cho, Suee Lee, Seok Yun Kang, Jae Hong Seo, Sung Bae Kim, Kyung Hae Jung

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose Eribulin mesilate was approved for the treatment of patients with locally advanced or metastatic breast cancer (MBC), who had received at least two chemotherapeutic regimens, including anthracycline and taxane. On the other hand, the efficacy and safety information of eribulin in Korean patients is limited by the lack of clinical trials. Materials and Methods In this multicenter, open-label, single-arm, phase IV study, locally advanced or MBC patients were enrolled between June 2013 and April 2014 from 14 centers in Korea. One point four mg/m2 dose of eribulin was administered on days 1 and 8 of every 21 days. The primary endpoint was the frequency and intensity of the treatment emergent adverse event. The secondary endpoint was the disease control rate, which included the rate of complete responses, partial responses, and stable disease. Results A total of 101 patients received at least one dose of eribulin and were included in the safety set. The patients received a total of 543 treatment cycles, with a median of three cycles (range, 1 to 31 cycles). The most common adverse event was neutropenia (91.1% of patients, 48.3% of cycles). The frequent non-hematological adverse events included alopecia, decrease in appetite, fatigue/asthenia, and myalgia/arthralgia. The peripheral neuropathy of any grade occurred in 27 patients (26.7%), including grade 3 in two patients. Disease control rate was 52.7% and 51.3% of patients in the full analysis set and per-protocol set, respectively. Conclusion This study demonstrated the feasible safety profile and activity of eribulin in Korean patients with MBC.

Original languageEnglish
Pages (from-to)423-429
Number of pages7
JournalCancer Research and Treatment
Volume49
Issue number2
DOIs
Publication statusPublished - 2017 Apr 1

Fingerprint

eribulin
Mesylates
Breast Neoplasms
Safety
Clinical Studies
Asthenia

Keywords

  • Breast neoplasms
  • Eribulin
  • Korean
  • Metastasis
  • Phase IV clinical trial
  • Safety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Feasibility and efficacy of eribulin mesilate in Korean patients with metastatic breast cancer : Korean multi-center phase IV clinical study results. / Park, Yeon Hee; Kim, Tae Yong; Im, Young Hyuck; Lee, Keun Seok; Park, In Hae; Sohn, Joohyuk; Lee, Soo Hyeon; Im, Seock Ah; Kim, Jee Hyun; Kim, Se Hyun; Lee, Soo Jung; Koh, Su Jin; Lee, Ki Hyeong; Choi, Yoon Ji; Cho, Eun Kyung; Lee, Suee; Kang, Seok Yun; Seo, Jae Hong; Kim, Sung Bae; Jung, Kyung Hae.

In: Cancer Research and Treatment, Vol. 49, No. 2, 01.04.2017, p. 423-429.

Research output: Contribution to journalArticle

Park, YH, Kim, TY, Im, YH, Lee, KS, Park, IH, Sohn, J, Lee, SH, Im, SA, Kim, JH, Kim, SH, Lee, SJ, Koh, SJ, Lee, KH, Choi, YJ, Cho, EK, Lee, S, Kang, SY, Seo, JH, Kim, SB & Jung, KH 2017, 'Feasibility and efficacy of eribulin mesilate in Korean patients with metastatic breast cancer: Korean multi-center phase IV clinical study results', Cancer Research and Treatment, vol. 49, no. 2, pp. 423-429. https://doi.org/10.4143/crt.2016.191
Park, Yeon Hee ; Kim, Tae Yong ; Im, Young Hyuck ; Lee, Keun Seok ; Park, In Hae ; Sohn, Joohyuk ; Lee, Soo Hyeon ; Im, Seock Ah ; Kim, Jee Hyun ; Kim, Se Hyun ; Lee, Soo Jung ; Koh, Su Jin ; Lee, Ki Hyeong ; Choi, Yoon Ji ; Cho, Eun Kyung ; Lee, Suee ; Kang, Seok Yun ; Seo, Jae Hong ; Kim, Sung Bae ; Jung, Kyung Hae. / Feasibility and efficacy of eribulin mesilate in Korean patients with metastatic breast cancer : Korean multi-center phase IV clinical study results. In: Cancer Research and Treatment. 2017 ; Vol. 49, No. 2. pp. 423-429.
@article{f35eac491bb44b3481f26dd4350e7516,
title = "Feasibility and efficacy of eribulin mesilate in Korean patients with metastatic breast cancer: Korean multi-center phase IV clinical study results",
abstract = "Purpose Eribulin mesilate was approved for the treatment of patients with locally advanced or metastatic breast cancer (MBC), who had received at least two chemotherapeutic regimens, including anthracycline and taxane. On the other hand, the efficacy and safety information of eribulin in Korean patients is limited by the lack of clinical trials. Materials and Methods In this multicenter, open-label, single-arm, phase IV study, locally advanced or MBC patients were enrolled between June 2013 and April 2014 from 14 centers in Korea. One point four mg/m2 dose of eribulin was administered on days 1 and 8 of every 21 days. The primary endpoint was the frequency and intensity of the treatment emergent adverse event. The secondary endpoint was the disease control rate, which included the rate of complete responses, partial responses, and stable disease. Results A total of 101 patients received at least one dose of eribulin and were included in the safety set. The patients received a total of 543 treatment cycles, with a median of three cycles (range, 1 to 31 cycles). The most common adverse event was neutropenia (91.1{\%} of patients, 48.3{\%} of cycles). The frequent non-hematological adverse events included alopecia, decrease in appetite, fatigue/asthenia, and myalgia/arthralgia. The peripheral neuropathy of any grade occurred in 27 patients (26.7{\%}), including grade 3 in two patients. Disease control rate was 52.7{\%} and 51.3{\%} of patients in the full analysis set and per-protocol set, respectively. Conclusion This study demonstrated the feasible safety profile and activity of eribulin in Korean patients with MBC.",
keywords = "Breast neoplasms, Eribulin, Korean, Metastasis, Phase IV clinical trial, Safety",
author = "Park, {Yeon Hee} and Kim, {Tae Yong} and Im, {Young Hyuck} and Lee, {Keun Seok} and Park, {In Hae} and Joohyuk Sohn and Lee, {Soo Hyeon} and Im, {Seock Ah} and Kim, {Jee Hyun} and Kim, {Se Hyun} and Lee, {Soo Jung} and Koh, {Su Jin} and Lee, {Ki Hyeong} and Choi, {Yoon Ji} and Cho, {Eun Kyung} and Suee Lee and Kang, {Seok Yun} and Seo, {Jae Hong} and Kim, {Sung Bae} and Jung, {Kyung Hae}",
year = "2017",
month = "4",
day = "1",
doi = "10.4143/crt.2016.191",
language = "English",
volume = "49",
pages = "423--429",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Society for Thoracic and Cardiovascular Surgery",
number = "2",

}

TY - JOUR

T1 - Feasibility and efficacy of eribulin mesilate in Korean patients with metastatic breast cancer

T2 - Korean multi-center phase IV clinical study results

AU - Park, Yeon Hee

AU - Kim, Tae Yong

AU - Im, Young Hyuck

AU - Lee, Keun Seok

AU - Park, In Hae

AU - Sohn, Joohyuk

AU - Lee, Soo Hyeon

AU - Im, Seock Ah

AU - Kim, Jee Hyun

AU - Kim, Se Hyun

AU - Lee, Soo Jung

AU - Koh, Su Jin

AU - Lee, Ki Hyeong

AU - Choi, Yoon Ji

AU - Cho, Eun Kyung

AU - Lee, Suee

AU - Kang, Seok Yun

AU - Seo, Jae Hong

AU - Kim, Sung Bae

AU - Jung, Kyung Hae

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Purpose Eribulin mesilate was approved for the treatment of patients with locally advanced or metastatic breast cancer (MBC), who had received at least two chemotherapeutic regimens, including anthracycline and taxane. On the other hand, the efficacy and safety information of eribulin in Korean patients is limited by the lack of clinical trials. Materials and Methods In this multicenter, open-label, single-arm, phase IV study, locally advanced or MBC patients were enrolled between June 2013 and April 2014 from 14 centers in Korea. One point four mg/m2 dose of eribulin was administered on days 1 and 8 of every 21 days. The primary endpoint was the frequency and intensity of the treatment emergent adverse event. The secondary endpoint was the disease control rate, which included the rate of complete responses, partial responses, and stable disease. Results A total of 101 patients received at least one dose of eribulin and were included in the safety set. The patients received a total of 543 treatment cycles, with a median of three cycles (range, 1 to 31 cycles). The most common adverse event was neutropenia (91.1% of patients, 48.3% of cycles). The frequent non-hematological adverse events included alopecia, decrease in appetite, fatigue/asthenia, and myalgia/arthralgia. The peripheral neuropathy of any grade occurred in 27 patients (26.7%), including grade 3 in two patients. Disease control rate was 52.7% and 51.3% of patients in the full analysis set and per-protocol set, respectively. Conclusion This study demonstrated the feasible safety profile and activity of eribulin in Korean patients with MBC.

AB - Purpose Eribulin mesilate was approved for the treatment of patients with locally advanced or metastatic breast cancer (MBC), who had received at least two chemotherapeutic regimens, including anthracycline and taxane. On the other hand, the efficacy and safety information of eribulin in Korean patients is limited by the lack of clinical trials. Materials and Methods In this multicenter, open-label, single-arm, phase IV study, locally advanced or MBC patients were enrolled between June 2013 and April 2014 from 14 centers in Korea. One point four mg/m2 dose of eribulin was administered on days 1 and 8 of every 21 days. The primary endpoint was the frequency and intensity of the treatment emergent adverse event. The secondary endpoint was the disease control rate, which included the rate of complete responses, partial responses, and stable disease. Results A total of 101 patients received at least one dose of eribulin and were included in the safety set. The patients received a total of 543 treatment cycles, with a median of three cycles (range, 1 to 31 cycles). The most common adverse event was neutropenia (91.1% of patients, 48.3% of cycles). The frequent non-hematological adverse events included alopecia, decrease in appetite, fatigue/asthenia, and myalgia/arthralgia. The peripheral neuropathy of any grade occurred in 27 patients (26.7%), including grade 3 in two patients. Disease control rate was 52.7% and 51.3% of patients in the full analysis set and per-protocol set, respectively. Conclusion This study demonstrated the feasible safety profile and activity of eribulin in Korean patients with MBC.

KW - Breast neoplasms

KW - Eribulin

KW - Korean

KW - Metastasis

KW - Phase IV clinical trial

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=85017364781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017364781&partnerID=8YFLogxK

U2 - 10.4143/crt.2016.191

DO - 10.4143/crt.2016.191

M3 - Article

VL - 49

SP - 423

EP - 429

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 2

ER -